Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG - ScienceDirect
Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Pr
Frontiers | The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression | Oncology
Potent antileukemic activity of curaxin CBL0137 against MLL‐rearranged leukemia - Somers - 2020 - International Journal of Cancer - Wiley Online Library
Acute exposure to CBL0137 decreases CD133 cell-surface expression and... | Download Scientific Diagram
Potent antileukemic activity of curaxin CBL0137 against MLL‐rearranged leukemia - Somers - 2020 - International Journal of Cancer - Wiley Online Library
Australian Researchers Find New Way to Target Deadly Childhood Cancer With CBL0137 | The Cure Starts Now
Potent antileukemic activity of curaxin CBL0137 against MLL‐rearranged leukemia - Somers - 2020 - International Journal of Cancer - Wiley Online Library
Stimulation of an anti-tumor immune response with “chromatin-damaging” therapy | SpringerLink
APExBIO - CBL0137 | curaxin that activates p53 and inhibits NF-κB | CAS# 1197996-80-7
The small molecule drug CBL0137 increases the level of DNA damage and the efficacy of radiotherapy for glioblastoma - ScienceDirect
Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG
Effective inhibition of MYC-amplified group 3 medulloblastoma by FACT-targeted curaxin drug CBL0137 | Cell Death & Disease
CBL0137 inhibits EPC in vitro. a A 13-nucleosome 601207 × 13 array for... | Download Scientific Diagram
Effective inhibition of MYC-amplified group 3 medulloblastoma by FACT-targeted curaxin drug CBL0137 | Cell Death & Disease
Effective inhibition of MYC-amplified group 3 medulloblastoma by FACT-targeted curaxin drug CBL0137 | Cell Death & Disease
Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pan
Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pan
Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG
Anticancer Drug Cbl0137 Highly Effective Against Infant Leukaemia | CCI
Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pan
New Strategy For Stubborn Neuroblastomas
IJMS | Free Full-Text | Exploring the Interaction of Curaxin CBL0137 with G-Quadruplex DNA Oligomers | HTML
CBL0137 HCl | ≥99%(HPLC) | Selleck | p53 activator
The small molecule drug CBL0137 increases the level of DNA damage and the efficacy of radiotherapy for glioblastoma - ScienceDirect
